The metastasis suppressor function of CD82 was first documented in a rat prostate cancer model [84], and also in a murine orthotopic lung cancer model [85], and in several other cancer cell models including hepatocarcinoma, melanoma, sarcoma, pancreatic and breast cancer affecting in vivo invasion and metastasis [40]. Here, CD82 is linked to prostate cancer.